Skip to main content
. Author manuscript; available in PMC: 2024 Jun 15.
Published in final edited form as: J Neuroimmunol. 2023 May 11;379:578105. doi: 10.1016/j.jneuroim.2023.578105

Fig. 2.

Fig. 2.

Metabolites with significant MR estimated effects on the risk of MS.

Odds ratios and 95% confidence intervals are scaled to per genetically predicted 1 SD increase in circulating metabolite levels. MR: Mendelian randomization; MS: multiple sclerosis; OR: odds ratios; 95% CI: 95% confidence intervals; SD: standard deviation; SNP: single nucleotide polymorphism.